Lymph Node Status & Tumor Size in Lung Cancer Adjuvant Therapy

Experts discuss the critical factors for recommending adjuvant chemotherapy after surgery for early-stage non-small cell lung cancer (NSCLC). They confirm that lymph node involvement (N1 disease) is a clear indicator for offering platinum-based chemotherapy due to the higher risk of recurrence.

For patients with node-negative disease, even with a 2.8 cm (T1c) tumor, the consensus is that surgery alone followed by active surveillance is the standard of care. The panel references data, such as the LACE meta-analysis, which suggested a potential detriment to chemotherapy in very early-stage (e.g., Stage IA) patients. They note that while genomic risk signatures are an emerging area of research, they are not yet standard for risk stratification in lung cancer. The final recommendation for this case, given the positive lymph node, is surgery followed by adjuvant chemotherapy.